LANdiolol MIcrocirculatory effects during Septic chOc (MILANOS)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512757-24-00

Acronym

APHP191047

Enrollment

Registered

2024-10-08

Start date

2022-07-18

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with microcirculatory abnormalities during septic shock

Brief summary

Variation (%) in microcirculatory vascular reactivity (T2-T0/T0x100).

Detailed description

Variation (%) in cardiac output (echocardiography), Variation (%) in clinical perfusion parameters between T0 and T2: mottling score, skin recoloration time, hourly diuresis, Variation (%) in arterial lactate clearance between T0 and T2, Variation (%) in systemic and endothelial inflammation parameters between T0 and T2 : Plasma cytokines (Procartaplex), VCAM-1 soluble, Soluble Endocan

Interventions

DRUGRAPIBLOC 300 mg

DRUGpoudre pour solution pour perfusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Variation (%) in microcirculatory vascular reactivity (T2-T0/T0x100).	—

Secondary

Measure	Time frame
Variation (%) in cardiac output (echocardiography), Variation (%) in clinical perfusion parameters between T0 and T2: mottling score, skin recoloration time, hourly diuresis, Variation (%) in arterial lactate clearance between T0 and T2, Variation (%) in systemic and endothelial inflammation parameters between T0 and T2 : Plasma cytokines (Procartaplex), VCAM-1 soluble, Soluble Endocan	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026